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OBJECTIVES: To retrospectively estimate the cost-effectiveness of adding zoledronic 
acid (ZOL; 4 mg intravenously q6m) to adjuvant endocrine therapy (ET; goserelin 
plus tamoxifen or anastrozole) in premenopausal women with endocrine-responsive 
early breast cancer (ERBC) from Italian, Spanish, and Portuguese health-care perspec-
tives. METHODS: A Markov model projected lifetime outcomes and costs of care for 
ERBC patients receiving 3 years’ adjuvant ET or adjuvant ET plus ZOL. Cost-effec-
tiveness was measured as the incremental cost per quality-adjusted life-year (QALY) 
gained. Probabilities of BC recurrence were from the ABCSG-12 trial. Other probabili-
ties and country-speciﬁ c costs were from published literature. Results were generated 
under two scenarios: 1) beneﬁ ts of ZOL persist to the 7-year maximum follow-up 
(trial beneﬁ t); 2) beneﬁ ts persist until recurrence or death (lifetime beneﬁ t). RESULTS: 
Expected ZOL costs (medication and administration) were c1500 (Italy), c2100 
(Spain), and c2300 (Portugal). Under the trial beneﬁ t scenario, resulting savings from 
reduced BC recurrence partially offset costs by c900 (both Spain and Italy) and c200 
(Portugal). Therefore, projected total ZOL costs were c600 (Italy), c1300 (Spain), and 
c2100 (Portugal). Projected QALY gains with ZOL were 0.46 (Italy), 0.47 (Spain), 
and 0.33 (Portugal). Costs per QALY gained were c1304 (Italy), c2766 (Spain), and 
c6364 (Portugal) (all favorable). Under the lifetime beneﬁ t scenario, savings from 
reduced BC recurrences completely offset ZOL costs and yielded net savings of c2900 
(Italy) and c2100 (Spain). Incremental total costs were c1400 for Portugal. Projected 
QALY gains with ZOL were 1.57 (Italy), 1.59 (Spain), and 0.96 (Portugal). The cost 
per QALY gained for Portugal was highly favorable (c1458). CONCLUSIONS: 
Adding ZOL to ET in premenopausal women with ERBC can be highly cost-effective 
(<c50,000 per QALY gained) in Italy, Spain, and Portugal. Additionally, ZOL would 
be considered cost saving to patients in Italy and Spain if these beneﬁ ts persist >7 
years.
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OBJECTIVES: This study aims to compare the guaiac-based fecal immunochemical 
test (FIT), the primary colorectal cancer (CRC) detection technique, with the fecal 
DNA (F-DNA) test which has been recommended as an alternative to FIT as the 
standard of care. METHODS: A hybrid decision tree-Markov model was created to 
estimate the CRC screening cost per quality-adjusted life-year (QALYs) of using the 
FIT annually, or the F-DNA every 3, or the F-DNA every 5 years in individuals at 
average CRC risk from a third-party payer’s perspective. a hypothetical cohort of 
10,000, 50-year-old individuals transitioning between the health states: healthy, 
polyps <10 mm, polyps >10 mm, local cancer, regional cancer, advanced cancer, and 
dead, were followed until they were 75 years. Colonoscopy followed every positive 
test result. Sensitivity, speciﬁ city, transition probabilities, and costs (in 2010 US 
Dollars) were obtained from clinical trials and published peer-reviewed articles. The 
costs and QALYs were discounted at 3% and sensitivity analyses were conducted. 
RESULTS: Using FIT annually would result in an average cost of $56,716.94/QALY 
for each individual with an incremental cost-effectiveness ratio (ICER) of $76,181/
QALY when compared to F-DNA used every 5 years. In the ICER plane of 1000 
Monte Carlo simulations, FIT was more costly but more effective technique compared 
to F-DNA used every 5 years, in 77% of the samples. FIT was the most cost-effective 
screening strategy at willingness to pay (WTP) of $100,000/QALY. However, at a 
lower WTP of $50,000/QALY, F-DNA every 5 years was cost-effective until a thresh-
old of $71,000/QALY. F-DNA conducted every 3 years was completely dominated 
by FIT. CONCLUSIONS: Further research is needed, and third-party payers may need 
to assess variables such as compliance and patient characteristics, before considering 
the F-DNA as a standard of care for screening CRC.
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OBJECTIVES: Chronic graft-versus-host disease (cGVHD) is a major complication 
after allogeneic hematopoietic stem cell transplantation (HSCT) that impairs quality 
of life, functional status, and long-term survival. There is no standard therapy for 
patients whose cGVHD does not resolve with immunosuppressors and corticosteroid 
treatment. The aim of this study was to compare the cost-effectiveness of extra-cor-
poreal photopheresis (ECP) with Rituximab (Rmb) or Imantinib (IMT) or pooled 
comparators (pooled) in addition to the usual care of cGvHD after standard treatment 
failure in Spain. METHODS: The model assessed the incremental cost-effectiveness 
ratio (ICER) of ECP versus Rmb or IMT or pooled comparator. The incremental cost 
and quality-adjusted life-year (QALY) gained were estimated using a short-term deci-
sion analysis and a long-term Markov cohort modeling approach. Model probabilities 
were obtained from literature, while treatment pathways and adverse event where 
derived from expert opinion. Local data on health resources use and costs were used 
and validated by clinical experts. The time horizon of the study was 5 years and only 
direct local medical costs (euros 2010) were considered. a probabilistic sensitivity 
analysis was performed. RESULTS: Preliminary results show that the higher efﬁ cacy 
of ECP leads to a gain of 0.19–0.20 QALY at ﬁ rst year and 0.15–0.19 at year 5 when 
compared to Rmb or IMT or pooled. The short-term cost of ECP is higher than Rmb 
(c2.900), IMT (c800) and pooled (c1.800). The ICER results for ECP for the ﬁ rst year 
were c15,340 versus RMB, c3.663 verus IMT and c8.977 versus pooled. At 3 years, 
ECP was dominant versus IMT and pooled, and showed ICER less than c3.000 vs. 
Rmb. The results of the evaluation were sensitive to limited data available. CONCLU-
SIONS: Preliminary results of this study indicate ECP is a cost-effective, below the 
Spanish threshold, or dominant option with respect altenatives.
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OBJECTIVES: Octreotide LAR has shown antiproliferative activity in advanced 
midgut neuroendocrine tumors (NET) increasing time to tumor progression (TTP) 
compared to placebo. This study aims to assess the costs and consequences of OCT-LA 
versus best supportive care (BSC) in patients with metastatic midgut NET from the 
private payer perspective. METHODS: A three health state (progression-free survival, 
progression, and death) Markov model with a 10-year time horizon was developed 
with data from the phase III PROMID trial. Within the trial, subjects remained on 
treatment until progression. Resource use was estimated through published data and 
input from clinical experts to reﬂ ect clinical practice in the Brazilian private setting. 
Unit costs were obtained from Brazilian ofﬁ cial sources. Costs and outcomes were 
discounted 5% per annum. RESULTS: The model estimated 14 months PFS with 
OCT-LA versus 6 months with BSC. Estimated PFS gain was 0.60 years (1.07 vs. 
0.46). Total cost of treatment was 275,497 BRL for BSC and 303,111 BRL for 
OCT-LA. The incremental cost per progression-free year gained was 28,706 BRL in 
the OCT-LA arm versus BSC due to treatment until progression. The mean cost of 
supportive care for progressive disease represented 87.3% (239,883 BRL) and 76.9% 
(224,388 BRL) of the ﬁ nal cost of treatment for BSC and OCT-LA, respectively. 
Results remained consistent when univariate sensitivity analyses were run. CONCLU-
SIONS: OCT-LA is a clinically effective option to control tumor growth in patients 
with metastatic midgut NET. OCT-LA provides longer TTP compared to BSC for 
those patients. Although there is ecological evidence to suggest improvement in OS 
after introduction of OCT LA, the ICER for an additional life-year gained is not cur-
rently calculable as the PROMID trial was not designed to evaluate OS. Further areas 
of research to elucidate the association between PFS and OS in NET are needed.
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OBJECTIVES: Imatinib is a low molecular tyrosine kinase inhibitor that blocks the 
kinase activity KIT and PDGFRα, and a ﬁ rst-line drug in the treatment of unresectable 
and metastatic gastrointestinal stromal tumor (GIST). The standard treatment of 
patients with localized primary GIST is a complete surgical resection of the tumor. 
Several studies have shown that target therapy improves survival of patients after GIST 
resection. The purpose of this study was to estimate the costs and effectiveness of 
adjuvant imatinib therapy versus no treatment in patients who have undergone GIST 
resection. METHODS: A Markov model was used to estimate costs and effectiveness 
of adjuvant imatinib therapy in the long-term follow-up period. Data on overall and 
recurrence-free survival were taken from the phase III clinical trial ACOSOG Z9001 
and were used to assess efﬁ cacy. Measures of effectiveness include such indicators as 
life-years saved and quality-adjusted life-years (QALYs) gained for adjuvant imatinib 
following surgical resection and surgical resection only. Data on the common practice 
of GIST treatment in the Russian oncology centers were used in the model. Costs, 
life-years, and QALYs gained were calculated over the 50-year time horizon and 
discounted at an annual rate of 5%. RESULTS: The number of life-years saved was 
10.01 for imatinib treatment against 8.67 for no treatment. The number of QALYs 
was 7.97 and 6.82, respectively. The costs of 1-year patient management with adju-
vant imatinib therapy were c44,348 per person; a patient who had not received 
imatinib in adjuvant mode required c32,102 per person. CONCLUSIONS: The analy-
sis showed that adjuvant imatinib therapy is more costly compared with no treatment. 
However, it is more effective and can increase the life expectancy of patients. In this 
